PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35443108-0	2022	Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.	Azacitidine	15-26	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	30-34	
35532213-1	2022	A recent phase III study shows that the combination of azacitidine with the IDH1 inhibitor ivosidenib is more effective than azacitidine alone in patients with acute myeloid leukemia who aren"t eligible for intensive chemotherapy.	Azacitidine	125-136	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	76-80	
35452083-1	2022	Two publications detailing the clinical outcomes of patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine provide new insights into risk stratification and set the stage for future trials integrating molecularly targeted therapy with this new standard regimen.	Azacitidine	175-186	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	106-110	
35443108-1	2022	BACKGROUND: The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia.	Azacitidine	107-118	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	216-220	
35046058-5	2022	RESULTS: IDH1/2mut were detected in 81 (26%) and 28 (22%) patients in the venetoclax+azacitidine and azacitidine groups.	Azacitidine	85-96	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	9-13	
35381683-0	2022	(Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report).	Azacitidine	134-145	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	61-65	
35046058-5	2022	RESULTS: IDH1/2mut were detected in 81 (26%) and 28 (22%) patients in the venetoclax+azacitidine and azacitidine groups.	Azacitidine	101-112	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	9-13	
35046058-6	2022	Composite complete remission (CRc, complete remission (CR)+CR with incomplete hematologic recovery (CRi)) rates (venetoclax+azacitidine/azacitidine) among patients with IDH1/2mut were 79%/11%, median duration of remission (mDoR) was 29.5/9.5 months, and median overall survival (mOS) was 24.5/6.2 months.	Azacitidine	124-135	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	169-173	
35046058-6	2022	Composite complete remission (CRc, complete remission (CR)+CR with incomplete hematologic recovery (CRi)) rates (venetoclax+azacitidine/azacitidine) among patients with IDH1/2mut were 79%/11%, median duration of remission (mDoR) was 29.5/9.5 months, and median overall survival (mOS) was 24.5/6.2 months.	Azacitidine	136-147	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	169-173	
35046058-10	2022	In IDH1/2 WT AML treated with venetoclax+azacitidine with poor-risk cytogenetics had inferior outcomes compared to IDH1/2mut, who had superior outcomes regardless of cytogenetic risk (mOS, IDH1/2mut: intermediate-risk, 24.5 months; poor-risk, NR; IDH1/2 WT: intermediate, 19.2 and poor, 7.4 months).	Azacitidine	41-52	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	3-7	
35046058-10	2022	In IDH1/2 WT AML treated with venetoclax+azacitidine with poor-risk cytogenetics had inferior outcomes compared to IDH1/2mut, who had superior outcomes regardless of cytogenetic risk (mOS, IDH1/2mut: intermediate-risk, 24.5 months; poor-risk, NR; IDH1/2 WT: intermediate, 19.2 and poor, 7.4 months).	Azacitidine	41-52	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	247-251	
35046058-12	2022	CONCLUSION: Patients with IDH1/2mut who receive venetoclax+azacitidine had high response rates, durable remissions and significant OS; cytogenetic risk did not mitigate the favorable outcomes seen from this regimen for IDH1/2mut.	Azacitidine	59-70	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	26-30	
35046058-12	2022	CONCLUSION: Patients with IDH1/2mut who receive venetoclax+azacitidine had high response rates, durable remissions and significant OS; cytogenetic risk did not mitigate the favorable outcomes seen from this regimen for IDH1/2mut.	Azacitidine	59-70	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	219-223	
32241846-0	2021	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.	Azacitidine	55-66	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	24-28	
32241846-0	2021	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.	Azacitidine	55-66	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	70-74	
24077805-0	2013	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.	Azacitidine	0-13	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	110-114	
33043739-0	2021	Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.	Azacitidine	11-22	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	43-49	
33292606-0	2020	Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML.	Azacitidine	93-106	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	20-24